Jade Biosciences (JBIO) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Jade Biosciences (JBIO) has outperformed Kura Oncology (KURA) over the past year, gaining 53.1% versus a gain of 3.4%. Over five years, KURA leads with a -41.2% price change compared with -97.1% for JBIO. Kura Oncology is the larger company by market cap ($943.0 million vs $915.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JBIO | KURA |
|---|---|---|
| Share price | $14.39 | $10.60 |
| Market cap | $915.17M | $942.98M |
| 1-day change | +1.70% | +0.76% |
| YTD return | -6.74% | +2.02% |
| 1-year return | +53.09% | +3.41% |
| 5-year return | -97.09% | -41.18% |
| EPS (TTM) | $-1.92 | $-3.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $67.48M |
| Revenue growth (YoY) | — | +25.24% |
| Net income (latest FY) | $-127.41M | $-278.67M |
| Operating margin | — | -449.94% |
| Net margin | — | -412.95% |
| 52-week high | $28.00 | $13.90 |
| 52-week low | $8.36 | $7.36 |
| Distance from 52-week high | -48.61% | -23.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +248.37% | +200.47% |
| Average volume | 894.02K | 1.77M |
| Shares outstanding | 63.60M | 88.96M |
| Employees | 55 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JBIO has outperformed KURA by 49.7 percentage points over the past year.
About Jade Biosciences
JBIO stock →Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
JBIO vs KURA FAQ
Which is bigger, Jade Biosciences or Kura Oncology?
Kura Oncology (KURA) is larger, with a market capitalization of $942.98M compared with $915.17M for Jade Biosciences (JBIO).
Which stock has performed better over the past year, JBIO or KURA?
JBIO returned +53.09% over the past 12 months, compared with +3.41% for KURA (price return, excluding dividends). Past performance does not predict future results.
Are Jade Biosciences and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.